首页 > 资讯 > Advances in gut microbiota

Advances in gut microbiota

泰然健康网
2024-12-28 21:03

[1] CANI PD. Human gut microbiome: hopes, threats and promises[J]. Gut, 2018, 67(9): 1716-1725 DOI:10.1136/gutjnl-2018-316723. [2] HADRICH D. Microbiome research is becoming the key to better understanding health and nutrition[J]. Frontiers in Genetics, 2018, 9: 212 DOI:10.3389/fgene.2018.00212. [3] JIN YP, DONG H, XIA LL, YANG Y, ZHU YQ, SHEN Y, ZHENG HJ, YAO CC, WANG Y, LU S. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2019, 14(8): 1378-1389 DOI:10.1016/j.jtho.2019.04.007. [4] GONG X, LI X, BO A, SHI RY, LI QY, LEI LJ, ZHANG L, LI MH. The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: a review[J]. Pharmacological Research, 2020, 157: 104824 DOI:10.1016/j.phrs.2020.104824. [5] ALMEIDA A, MITCHELL AL, BOLAND M, FORSTER SC, GLOOR GB, TARKOWSKA A, LAWLEY TD, FINN RD. A new genomic blueprint of the human gut microbiota[J]. Nature, 2019, 568(7753): 499-504 DOI:10.1038/s41586-019-0965-1. [6] GROCHOWSKA M, LASKUS T, RADKOWSKI M. Gut microbiota in neurological disorders[J]. Archivum Immunologiae et Therapiae Experimentalis, 2019, 67(6): 375-383 DOI:10.1007/s00005-019-00561-6. [7] WANG ZZ, QIN X, HU DX, HUANG J, GUO ES, XIAO RR, LI WT, SUN CY, CHEN G. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer[J]. Cell Reports, 2022, 41(13): 111890 DOI:10.1016/j.celrep.2022.111890. [8] CANI PD, DEPOMMIER C, DERRIEN M, EVERARD A, de VOS WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms[J]. Nature Reviews Gastroenterology & Hepatology, 2022, 19(10): 625-637. [9] BOLTE LA, VICH VILA A, IMHANN F, COLLIJ V, GACESA R, PETERS V, WIJMENGA C, KURILSHIKOV A, CAMPMANS-KUIJPERS MJE, FU JY, DIJKSTRA G, ZHERNAKOVA A, WEERSMA RK. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome[J]. Gut, 2021, 70(7): 1287-1298 DOI:10.1136/gutjnl-2020-322670. [10] HASHEM NM, GONZALEZ-BULNES A. The use of probiotics for management and improvement of reproductive eubiosis and function[J]. Nutrients, 2022, 14(4): 902 DOI:10.3390/nu14040902. [11] LIU M, XIE WJ, WAN XY, DENG T. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice[J]. International Immunopharmacology, 2020, 88: 106862 DOI:10.1016/j.intimp.2020.106862. [12] CHOI Y, LICHTERMAN JN, COUGHLIN LA, POULIDES N, LI WL, del VALLE P, PALMER SN, GAN SH, KIM J, ZHAN XW, GAO YJ, EVERS BM, HOOPER LV, PASARE C, KOH AY. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity[J]. Science Immunology, 2023, 8(81): eabo2003 DOI:10.1126/sciimmunol.abo2003. [13] CHEN SF, REN ZY, HUO YL, YANG WY, PENG LL, LV HH, NIE LG, WEI H, WAN CX. Targeting the gut microbiota to investigate the mechanism of Lactiplantibacillus plantarum 1201 in negating colitis aggravated by a high-salt diet[J]. Food Research International, 2022, 162: 112010 DOI:10.1016/j.foodres.2022.112010. [14] LIU LW, XIE Y, LI GQ, ZHANG T, SUI YH, ZHAO ZJ, ZHANG YY, YANG WB, GENG XL, XUE DB, CHEN H, WANG YW, LU TQ, SHANG LR, LI ZB, LI L, SUN B. Gut microbiota-derived nicotinamide mononucleotide alleviates acute pancreatitis by activating pancreatic SIRT3 signalling[J]. British Journal of Pharmacology, 2023, 180(5): 647-666 DOI:10.1111/bph.15980. [15] LIN DF, SUN QY, LIU ZY, PAN JX, ZHU J, WANG SW, JIA SN, ZHENG MH, LI XK, GONG FH. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice[J]. Free Radical Biology & Medicine, 2023, 195: 199-218. [16] SONG J, ZHOU B, KAN JT, LIU GY, ZHANG S, SI L, ZHANG XP, YANG X, MA JH, CHENG JR, YANG YD, LIU XB. Gut microbiota: linking nutrition and perinatal depression[J]. Frontiers in Cellular and Infection Microbiology, 2022, 12: 932309 DOI:10.3389/fcimb.2022.932309. [17] MARTINEZ-GURYN K, HUBERT N, FRAZIER K, URLASS S, MUSCH MW, OJEDA P, PIERRE JF, MIYOSHI J, SONTAG TJ, CHAM CM, REARDON CA, LEONE V, CHANG EB. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids[J]. Cell Host & Microbe, 2018, 23(4): 458-469.e5. [18] CHATTOPADHYAY I, DHAR R, PETHUSAMY K, SEETHY A, SRIVASTAVA T, SAH R, SHARMA J, KARMAKAR S. Exploring the role of gut microbiome in colon cancer[J]. Applied Biochemistry and Biotechnology, 2021, 193(6): 1780-1799 DOI:10.1007/s12010-021-03498-9. [19] KIM DS, WOO JS, MIN HK, CHOI JW, MOON JH, PARK MJ, KWOK SK, PARK SH, CHO ML. Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren's syndrome[J]. Journal of Autoimmunity, 2021, 119: 102611 DOI:10.1016/j.jaut.2021.102611. [20] LIN LY, ZHANG KY, XIONG Q, ZHANG JL, CAI B, HUANG ZC, YANG B, WEI B, CHEN J, NIU Q. Gut microbiota in pre-clinical rheumatoid arthritis: from pathogenesis to preventing progression[J]. Journal of Autoimmunity, 2023 DOI:10.1016/j.jaut.2023.103001. [21] LI Y, LUO ZY, HU YY, BI YW, YANG JM, ZOU WJ, SONG YL, LI S, SHEN T, LI SJ, HUANG L, ZHOU AJ, GAO TM, LI JM. The gut microbiota regulates autism-like behavior by mediating vitamin B6 homeostasis in EphB6-deficient mice[J]. Microbiome, 2020, 8(1): 120 DOI:10.1186/s40168-020-00884-z. [22] CHEN LM, WANG DM, GARMAEVA S, KURILSHIKOV A, VILA AV, GACESA R, SINHA T, STUDY LC, SEGAL E, WEERSMA RK, WIJMENGA C, ZHERNAKOVA A, FU JY. The long-term genetic stability and individual specificity of the human gut microbiome[J]. Cell, 2021, 184(9): 2302-2315.e12 DOI:10.1016/j.cell.2021.03.024. [23] FALONY G, JOOSSENS M, VIEIRA-SILVA S, WANG J, DARZI Y, FAUST K, KURILSHIKOV A, BONDER MJ, VALLES-COLOMER M, VANDEPUTTE D, TITO RY, CHAFFRON S, RYMENANS L, VERSPECHT C, de SUTTER L, LIMA-MENDEZ G, D'HOE K, JONCKHEERE K, HOMOLA D, GARCIA R, et al. Population-level analysis of gut microbiome variation[J]. Science, 2016, 352(6285): 560-564 DOI:10.1126/science.aad3503. [24] ZHERNAKOVA A, KURILSHIKOV A, BONDER MJ, TIGCHELAAR EF, SCHIRMER M, VATANEN T, MUJAGIC Z, VILA AV, FALONY G, VIEIRA-SILVA S, WANG J, IMHANN F, BRANDSMA E, JANKIPERSADSING SA, JOOSSENS M, CENIT MC, DEELEN P, SWERTZ MA, STUDY LC, WEERSMA RK, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science, 2016, 352(6285): 565-569 DOI:10.1126/science.aad3369. [25] CHEN CY, HUANG XC, FANG SM, YANG H, HE MZ, ZHAO YZ, HUANG LS. Contribution of host genetics to the variation of microbial composition of cecum lumen and feces in pigs[J]. Frontiers in Microbiology, 2018, 9: 2626 DOI:10.3389/fmicb.2018.02626. [26] BADAL VD, VACCARIELLO ED, MURRAY ER, YU KE, KNIGHT R, JESTE DV, NGUYEN TT. The gut microbiome, aging, and longevity: a systematic review[J]. Nutrients, 2020, 12(12): 3759 DOI:10.3390/nu12123759. [27] GOMAA EZ. Human gut microbiota/microbiome in health and diseases: a review[J]. Antonie Van Leeuwenhoek, 2020, 113(12): 2019-2040 DOI:10.1007/s10482-020-01474-7. [28] SCOTT AJ, ALEXANDER JL, MERRIFIELD CA, CUNNINGHAM D, JOBIN C, BROWN R, ALVERDY J, O'KEEFE SJ, GASKINS HR, TEARE J, YU J, HUGHES DJ, VERSTRAELEN H, BURTON J, O'TOOLE PW, ROSENBERG DW, MARCHESI JR, KINROSS JM. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis[J]. Gut, 2019, 68(9): 1624-1632 DOI:10.1136/gutjnl-2019-318556. [29] ROY S, TRINCHIERI G. Microbiota: a key orchestrator of cancer therapy[J]. Nature Reviews Cancer, 2017, 17(5): 271-285 DOI:10.1038/nrc.2017.13. [30] WU H, TREMAROLI V, SCHMIDT C, LUNDQVIST A, OLSSON LM, KRÄMER M, GUMMESSON A, PERKINS R, BERGSTRÖM G, BÄCKHED F. The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study[J]. Cell Metabolism, 2020, 32(3): 379-390.e3 DOI:10.1016/j.cmet.2020.06.011. [31] ABENAVOLI L, SCARPELLINI E, COLICA C, BOCCUTO L, SALEHI B, SHARIFI-RAD J, AIELLO V, ROMANO B, de LORENZO A, IZZO AA, CAPASSO R. Gut microbiota and obesity: a role for probiotics[J]. Nutrients, 2019, 11(11): 2690 DOI:10.3390/nu11112690. [32] BORSOM EM, CONN K, KEEFE CR, HERMAN C, ORSINI GM, HIRSCH AH, PALMA AVILA M, TESTO G, JARAMILLO SA, BOLYEN E, LEE K, CAPORASO JG, COPE EK. Predicting neurodegenerative disease using prepathology gut microbiota composition: a longitudinal study in mice modeling Alzheimer's disease pathologies[J]. Microbiology Spectrum, 2023, 11(2): e0345822 DOI:10.1128/spectrum.03458-22. [33] YANG SS, LI Y, WANG B, YANG N, HUANG X, CHEN QB, GENG SX, ZHOU YW, SHI H, WANG LY, BRUGMAN S, SAVELKOUL H, LIU GL. Acute porcine epidemic diarrhea virus infection reshapes the intestinal microbiota[J]. Virology, 2020, 548: 200-212 DOI:10.1016/j.virol.2020.07.001. [34] ASNICAR F, BERRY SE, VALDES AM, NGUYEN LH, PICCINNO G, DREW DA, LEEMING E, GIBSON R, le ROY C, AL KHATIB H, FRANCIS L, MAZIDI M, MOMPEO O, VALLES-COLOMER M, TETT A, BEGHINI F, DUBOIS L, BAZZANI D, THOMAS AM, MIRZAYI C, et al. Microbiome connections with host metabolism and habitual diet from 1 098 deeply phenotyped individuals[J]. Nature Medicine, 2021, 27(2): 321-332 DOI:10.1038/s41591-020-01183-8. [35] RINNINELLA E, CINTONI M, RAOUL P, LOPETUSO LR, SCALDAFERRI F, PULCINI G, MIGGIANO GAD, GASBARRINI A, MELE MC. Food components and dietary habits: keys for a healthy gut microbiota composition[J]. Nutrients, 2019, 11(10): 2393 DOI:10.3390/nu11102393. [36] VALLES-COLOMER M, BLANCO-MÍGUEZ A, MANGHI P, ASNICAR F, DUBOIS L, GOLZATO D, ARMANINI F, CUMBO F, HUANG KD, MANARA S, MASETTI G, PINTO F, PIPERNI E, PUNČOCHÁŘ M, RICCI L, ZOLFO M, FARRANT O, GONCALVES A, SELMA-ROYO M, BINETTI AG, et al. The person-to-person transmission landscape of the gut and oral microbiomes[J]. Nature, 2023, 614(7946): 125-135 DOI:10.1038/s41586-022-05620-1. [37] YANG JF, FENG PY, LING ZM, KHAN A, WANG X, CHEN YL, ALI G, FANG YT, SALAMA ES, WANG XM, LIU P, LI XK. Nickel exposure induces gut microbiome disorder and serum uric acid elevation[J]. Environmental Pollution, 2023, 324: 121349 DOI:10.1016/j.envpol.2023.121349. [38] ZIMMERMANN P, CURTIS N. The effect of antibiotics on the composition of the intestinal microbiota-a systematic review[J]. The Journal of Infection, 2019, 79(6): 471-489 DOI:10.1016/j.jinf.2019.10.008. [39] MAIER LS, PRUTEANU M, KUHN M, ZELLER G, TELZEROW A, ANDERSON EE, BROCHADO AR, FERNANDEZ KC, DOSE H, MORI H, PATIL KR, BORK P, TYPAS A. Extensive impact of non-antibiotic drugs on human gut bacteria[J]. Nature, 2018, 555(7698): 623-628 DOI:10.1038/nature25979. [40] HUGHES RL. A review of the role of the gut microbiome in personalized sports nutrition[J]. Frontiers in Nutrition, 2020, 6: 191 DOI:10.3389/fnut.2019.00191. [41] BIEDERMANN L, ZEITZ J, MWINYI J, SUTTER-MINDER E, REHMAN A, OTT SJ, STEURER-STEY C, FREI A, FREI P, SCHARL M, LOESSNER MJ, VAVRICKA SR, FRIED M, SCHREIBER S, SCHUPPLER M, ROGLER G. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans[J]. PLoS One, 2013, 8(3): e59260 DOI:10.1371/journal.pone.0059260. [42] SEN P, MOLINERO-PEREZ A, O'RIORDAN KJ, MCCAFFERTY CP, O'HALLORAN KD, CRYAN JF. Microbiota and sleep: awakening the gut feeling[J]. Trends in Molecular Medicine, 2021, 27(10): 935-945 DOI:10.1016/j.molmed.2021.07.004. [43] ANGELUCCI F, CECHOVA K, AMLEROVA J, HORT J. Antibiotics, gut microbiota, and Alzheimer's disease[J]. Journal of Neuroinflammation, 2019, 16(1): 108 DOI:10.1186/s12974-019-1494-4. [44] HAO HH, YAO JP, WU QH, WEI YJ, DAI MH, IQBAL Z, WANG X, WANG YL, HUANG LL, CHEN DM, TAO YF, LIU ZL, YUAN ZH. Microbiological toxicity of tilmicosin on human colonic microflora in chemostats[J]. Regulatory Toxicology and Pharmacology, 2015, 73(1): 201-208 DOI:10.1016/j.yrtph.2015.07.008. [45] HAO HH, ZHOU SX, CHENG GY, DAI MH, WANG X, LIU ZL, WANG YL, YUAN ZH. Effect of tulathromycin on colonization resistance, antimicrobial resistance, and virulence of human gut microbiota in chemostats[J]. Frontiers in Microbiology, 2016, 7: 477. [46] HAO HH, GUO WG, IQBAL Z, CHENG GY, WANG X, DAI MH, HUANG LL, WANG YL, PENG DP, LIU ZL, YUAN ZH. Impact of cyadox on human colonic microflora in chemostat models[J]. Regulatory Toxicology and Pharmacology, 2013, 67(3): 335-343 DOI:10.1016/j.yrtph.2013.08.011. [47] MAIER LS, GOEMANS CV, WIRBEL J, KUHN M, EBERL C, PRUTEANU M, MÜLLER P, GARCIA-SANTAMARINA S, CACACE E, ZHANG BY, GEKELER C, BANERJEE T, ANDERSON EE, MILANESE A, LÖBER U, FORSLUND SK, PATIL KR, ZIMMERMANN M, STECHER B, ZELLER G, et al. Unravelling the collateral damage of antibiotics on gut bacteria[J]. Nature, 2021, 599(7883): 120-124 DOI:10.1038/s41586-021-03986-2. [48] THANH DUY P, THI NGUYEN TN, VU THUY D, CHUNG THE H, ALCOCK F, BOINETT C, DAN THANH HN, THANH TUYEN H, THWAITES GE, RABAA MA, BAKER S. Commensal Escherichia coli are a reservoir for the transfer of XDR plasmids into epidemic fluoroquinolone-resistant Shigella sonnei[J]. Nature Microbiology, 2020, 5(2): 256-264 DOI:10.1038/s41564-019-0645-9. [49] KIENESBERGER S, COSIC A, KITSERA M, RAFFL S, HIESINGER M, LEITNER E, HALWACHS B, GORKIEWICZ G, GLABONJAT RA, RABER G, LEMBACHER-FADUM C, BREINBAUER R, SCHILD S, ZECHNER EL. Enterotoxin tilimycin from gut-resident Klebsiella promotes mutational evolution and antibiotic resistance in mice[J]. Nature Microbiology, 2022, 7(11): 1834-1848 DOI:10.1038/s41564-022-01260-3. [50] CABRAL DJ, PENUMUTCHU S, REINHART EM, ZHANG C, KORRY BJ, WURSTER JI, NILSON R, GUANG A, SANO WH, ROWAN-NASH AD, LI H, BELENKY P. Microbial metabolism modulates antibiotic susceptibility within the murine gut microbiome[J]. Cell Metabolism, 2019, 30(4): 800-823.e7 DOI:10.1016/j.cmet.2019.08.020. [51] SHI DY, HAO H, WEI ZL, YANG D, YIN J, LI HB, CHEN ZS, YANG ZW, CHEN TJ, ZHOU SQ, WU HY, LI JW, JIN M. Combined exposure to non-antibiotic pharmaceutics and antibiotics in the gut synergistically promote the development of multi-drug-resistance in Escherichia coli[J]. Gut Microbes, 2022, 14(1): 2018901 DOI:10.1080/19490976.2021.2018901. [52] ROBINSON M, HORN J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know[J]. Drugs, 2003, 63(24): 2739-2754 DOI:10.2165/00003495-200363240-00004. [53] MAFI JN, MAY FP, KAHN KL, CHONG M, CORONA E, YANG L, MONGARE MM, NAIR V, REYNOLDS C, GUPTA R, DAMBERG CL, ESRAILIAN E, SARKISIAN C. Low-value proton pump inhibitor prescriptions among older adults at a large academic health system[J]. Journal of the American Geriatrics Society, 2019, 67(12): 2600-2604 DOI:10.1111/jgs.16117. [54] WILLEMS RPJ, van DIJK K, KET JCF, VANDENBROUCKE-GRAULS CMJE. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms[J]. JAMA Internal Medicine, 2020, 180(4): 561-571 DOI:10.1001/jamainternmed.2020.0009. [55] WILLEMS RPJ, SCHUT MC, KAISER AM, GROOT TH, ABU-HANNA A, TWISK JWR, van DIJK K, VANDENBROUCKE-GRAULS CMJE. Association of proton pump inhibitor use with risk of acquiring drug-resistant enterobacterales[J]. JAMA Network Open, 2023, 6(2): e230470 DOI:10.1001/jamanetworkopen.2023.0470. [56] LIN CY, CHENG HT, KUO CJ, LEE YS, SUNG CM, KEIDAN M, RAO K, KAO JY, HSIEH SY. Proton pump inhibitor-induced gut dysbiosis increases mortality rates for patients with Clostridioides difficile infection[J]. Microbiology Spectrum, 2022, 10(4): e0048622 DOI:10.1128/spectrum.00486-22. [57] HOJO M, ASAHARA T, NAGAHARA A, TAKEDA T, MATSUMOTO K, UEYAMA H, MATSUMOTO K, ASAOKA D, TAKAHASHI T, NOMOTO K, YAMASHIRO Y, WATANABE S. Gut microbiota composition before and after use of proton pump inhibitors[J]. Digestive Diseases and Sciences, 2018, 63(11): 2940-2949 DOI:10.1007/s10620-018-5122-4. [58] REVELES KR, RYAN CN, CHAN L, COSIMI RA, HAYNES WL. Proton pump inhibitor use associated with changes in gut microbiota composition[J]. Gut, 2018, 67(7): 1369-1370 DOI:10.1136/gutjnl-2017-315306. [59] IMHANN F, BONDER MJ, VICH VILA A, FU JY, MUJAGIC Z, VORK L, TIGCHELAAR EF, JANKIPERSADSING SA, CENIT MC, HARMSEN HJM, DIJKSTRA G, FRANKE L, XAVIER RJ, JONKERS D, WIJMENGA C, WEERSMA RK, ZHERNAKOVA A. Proton pump inhibitors affect the gut microbiome[J]. Gut, 2016, 65(5): 740-748 DOI:10.1136/gutjnl-2015-310376. [60] JACKSON MA, GOODRICH JK, MAXAN ME, FREEDBERG DE, ABRAMS JA, POOLE AC, SUTTER JL, WELTER D, LEY RE, BELL JT, SPECTOR TD, STEVES CJ. Proton pump inhibitors alter the composition of the gut microbiota[J]. Gut, 2016, 65(5): 749-756 DOI:10.1136/gutjnl-2015-310861. [61] GOMMERS LMM, EDERVEEN THA, WIJST J, OVERMARS-BOS C, KORTMAN GAM, BOEKHORST J, BINDELS RJM, BAAIJ JHF, HOENDEROP JGJ. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia[J]. The FASEB Journal, 2019, 33(10): 11235-11246 DOI:10.1096/fj.201900839R. [62] FLORY J, LIPSKA K. Metformin in 2019[J]. JAMA, 2019, 321(19): 1926-1927 DOI:10.1001/jama.2019.3805. [63] LaMOIA TE, SHULMAN GI. Cellular and molecular mechanisms of metformin action[J]. Endocrine Reviews, 2021, 42(1): 77-96 DOI:10.1210/endrev/bnaa023. [64] FENG J, WANG XH, YE XC, ARES I, LOPEZ-TORRES B, MARTÍNEZ M, MARTÍNEZ-LARRAÑAGA MR, WANG X, ANADÓN A, MARTÍNEZ MA. Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications[J]. Pharmacological Research, 2022, 177: 106114 DOI:10.1016/j.phrs.2022.106114. [65] FORSLUND K, HILDEBRAND F, NIELSEN T, FALONY G, le CHATELIER E, SUNAGAWA S, PRIFTI E, VIEIRA-SILVA S, GUDMUNDSDOTTIR V, KROGH PEDERSEN H, ARUMUGAM M, KRISTIANSEN K, YVONNE VOIGT A, VESTERGAARD H, HERCOG R, IGOR COSTEA P, ROAT KULTIMA J, LI JH, JØRGENSEN T, LEVENEZ F, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota[J]. Nature, 2015, 528(7581): 262-266 DOI:10.1038/nature15766. [66] SUN LL, XIE C, WANG G, WU Y, WU Q, WANG XM, LIU J, DENG YY, XIA JL, CHEN B, ZHANG SY, YUN CY, LIAN G, ZHANG XJ, ZHANG H, BISSON WH, SHI JM, GAO XX, GE PP, LIU CH, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin[J]. Nature Medicine, 2018, 24(12): 1919-1929 DOI:10.1038/s41591-018-0222-4. [67] MUELLER NT, DIFFERDING MK, ZHANG MY, MARUTHUR NM, JURASCHEK SP, MILLER ER 3rd, APPEL LJ, YEH HC. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a randomized trial[J]. Diabetes Care, 2021, 44(7): 1462-1471 DOI:10.2337/dc20-2257. [68] BAUER PV, DUCA FA, WAISE TMZ, RASMUSSEN BA, ABRAHAM MA, DRANSE HJ, PURI A, O'BRIEN CA, LAM TKT. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway[J]. Cell Metabolism, 2018, 27(1): 101-117.e5 DOI:10.1016/j.cmet.2017.09.019. [69] KULKARNI AS, GUBBI S, BARZILAI N. Benefits of metformin in attenuating the hallmarks of aging[J]. Cell Metabolism, 2020, 32(1): 15-30 DOI:10.1016/j.cmet.2020.04.001. [70] MOHAMMED I, HOLLENBERG MD, DING H, TRIGGLE CR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan[J]. Frontiers in Endocrinology, 2021, 12: 718942 DOI:10.3389/fendo.2021.718942. [71] CABREIRO F, AU C, LEUNG KY, VERGARA-IRIGARAY N, COCHEMÉ HM, NOORI T, WEINKOVE D, SCHUSTER E, GREENE NDE, GEMS D. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism[J]. Cell, 2013, 153(1): 228-239 DOI:10.1016/j.cell.2013.02.035. [72] BRYRUP T, THOMSEN CW, KERN T, ALLIN KH, BRANDSLUND I, JØRGENSEN NR, VESTERGAARD H, HANSEN T, HANSEN TH, PEDERSEN O, NIELSEN T. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study[J]. Diabetologia, 2019, 62(6): 1024-1035 DOI:10.1007/s00125-019-4848-7. [73] DIVICCARO S, GIATTI S, CIOFFI L, FALVO E, PIAZZA R, CARUSO D, MELCANGI RC. Paroxetine effects in adult male rat colon: focus on gut steroidogenesis and microbiota[J]. Psychoneuroendocrinology, 2022, 143: 105828 DOI:10.1016/j.psyneuen.2022.105828. [74] ZHANG WJ, QU W, WANG H, YAN H. Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress[J]. Translational Psychiatry, 2021, 11: 131 DOI:10.1038/s41398-021-01254-5. [75] SHEN Y, YANG X, LI GF, GAO JY, LIANG Y. The change of gut microbiota in MDD patients under SSRIs treatment[J]. Scientific Reports, 2021, 11: 14918 DOI:10.1038/s41598-021-94481-1. [76] DENG XR, ZHANG CH, WANG PX, WEI W, SHI XY, WANG PP, YANG JP, WANG LM, TANG SS, FANG YY, LIU YL, CHEN YQ, ZHANG Y, YUAN Q, SHANG J, KAN Q, YANG HH, MAN H, WANG DY, YUAN HJ. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes[J]. The Journal of Clinical Endocrinology & Metabolism, 2022, 107(7): 1888-1896. [77] ZHANG HY, TIAN JX, LIAN FM, LI M, LIU WK, ZHEN Z, LIAO JQ, TONG XL. Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota[J]. Biomedicine & Pharmacotherapy, 2021, 133: 110857. [78] GU W, WANG YF, ZENG LX, DONG JC, BI Q, YANG XX, CHE YY, HE S, YU J. Polysaccharides from Polygonatum kingianum improve glucose and lipid metabolism in rats fed a high fat diet[J]. Biomedicine & Pharmacotherapy, 2020, 125: 109910. [79] WANG P, GAO JP, KE WX, WANG J, LI DT, LIU RL, JIA Y, WANG XH, CHEN X, CHEN F, HU XS. Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota[J]. Free Radical Biology & Medicine, 2020, 156: 83-98. [80] FU J, LI JX, SUN YZ, LIU S, SONG FR, LIU ZY. In-depth investigation of the mechanisms of Schisandra chinensis polysaccharide mitigating Alzheimer's disease rat via gut microbiota and feces metabolomics[J]. International Journal of Biological Macromolecules, 2023, 232: 123488 DOI:10.1016/j.ijbiomac.2023.123488. [81] LI MY, GUO WN, DONG YL, WANG WZ, TIAN CX, ZHANG ZL, YU T, ZHOU HF, GUI Y, XUE KM, LI JY, JIANG F, SARAPULTSEV A, WANG HF, ZHANG G, LUO SS, FAN H, HU DS. Beneficial effects of celastrol on immune balance by modulating gut microbiota in experimental ulcerative colitis mice[J]. Genomics, Proteomics & Bioinformatics, 2022, 20(2): 288-303. [82] LI DT, FENG Y, TIAN ML, JI JF, HU XS, CHEN F. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation[J]. Microbiome, 2021, 9(1): 83 DOI:10.1186/s40168-021-01028-7. [83] GINGELL R, BRIDGES JW, WILLIAMS RT. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat[J]. Xenobiotica, 1971, 1(2): 143-156 DOI:10.3109/00498257109044386. [84] SOUSA T, YADAV V, ZANN V, BORDE A, ABRAHAMSSON B, BASIT AW. On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid[J]. Journal of Pharmaceutical Sciences, 2014, 103(10): 3171-3175 DOI:10.1002/jps.24103. [85] SHIM SB, KIM NJ, KIM DH. β-glucuronidase inhibitory activity and hepatoprotective effect of 18β-glycyrrhetinic acid from the rhizomes of Glycyrrhiza uralensis[J]. Planta Medica, 2000, 66(1): 40-43 DOI:10.1055/s-2000-11109. [86] LEE CH, PARK SW, KIM YS, KANG SS, KIM JA, LEE SH, LEE SM. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice[J]. Biological and Pharmaceutical Bulletin, 2007, 30(10): 1898-1904 DOI:10.1248/bpb.30.1898. [87] AKAO T, HAYASHI T, KOBASHI K, KANAOKA M, KATO H, KOBAYASHI M, TAKEDA S, OYAMA T. Intestinal bacterial hydrolysis is indispensable to absorption of 18β-glycyrrhetic acid after oral administration of glycyrrhizin in rats[J]. Journal of Pharmacy and Pharmacology, 2011, 46(2): 135-137 DOI:10.1111/j.2042-7158.1994.tb03756.x. [88] KIM DH. Gut microbiota-mediated pharmacokinetics of ginseng saponins[J]. Journal of Ginseng Research, 2018, 42(3): 255-263 DOI:10.1016/j.jgr.2017.04.011. [89] GUTHRIE L, GUPTA S, DAILY J, KELLY L. Human microbiome signatures of differential colorectal cancer drug metabolism[J]. NPJ Biofilms and Microbiomes, 2017, 3: 27 DOI:10.1038/s41522-017-0034-1. [90] ZHAO RS, COKER OO, WU JL, ZHOU YF, ZHAO LY, NAKATSU G, BIAN XQ, WEI H, CHAN AWH, SUNG JJY, CHAN FKL, EL-OMAR E, YU J. Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects[J]. Gastroenterology, 2020, 159(3): 969-983.e4 DOI:10.1053/j.gastro.2020.05.004. [91] BALAICH J, ESTRELLA M, WU GJ, JEFFREY PD, BISWAS A, ZHAO LP, KORENNYKH A, DONIA MS. The human microbiome encodes resistance to the antidiabetic drug acarbose[J]. Nature, 2021, 600(7887): 110-115 DOI:10.1038/s41586-021-04091-0. [92] YAN A, CULP E, PERRY J, LAU JT, MacNEIL LT, SURETTE MG, WRIGHT GD. Transformation of the anticancer drug doxorubicin in the human gut microbiome[J]. ACS Infectious Diseases, 2018, 4(1): 68-76 DOI:10.1021/acsinfecdis.7b00166. [93] DELOMÉNIE C, FOUIX S, LONGUEMAUX S, BRAHIMI N, BIZET C, PICARD B, DENAMUR E, DUPRET JM. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid[J]. Journal of Bacteriology, 2001, 183(11): 3417-3427 DOI:10.1128/JB.183.11.3417-3427.2001. [94] ZIMMERMANN M, ZIMMERMANN-KOGADEEVA M, WEGMANN R, GOODMAN AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity[J]. Science, 2019, 363(6427): eaat9931 DOI:10.1126/science.aat9931. [95] TAKENO S, SAKAI T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction[J]. Teratology, 1991, 44(2): 209-214 DOI:10.1002/tera.1420440209. [96] HARRIS BE, MANNING BW, FEDERLE TW, DIASIO RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora[J]. Antimicrobial Agents and Chemotherapy, 1986, 29(1): 44-48 DOI:10.1128/AAC.29.1.44. [97] ROUTY B, le CHATELIER E, DEROSA L, DUONG CPM, ALOU MT, DAILLÈRE R, FLUCKIGER A, MESSAOUDENE M, RAUBER C, ROBERTI MP, FIDELLE M, FLAMENT C, POIRIER-COLAME V, OPOLON P, KLEIN C, IRIBARREN K, MONDRAGÓN L, JACQUELOT N, QU B, FERRERE G, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97 DOI:10.1126/science.aan3706. [98] SUN ZZ, LI XY, WANG S, SHEN L, JI HF. Bidirectional interactions between curcumin and gut microbiota in transgenic mice with Alzheimer's disease[J]. Applied Microbiology and Biotechnology, 2020, 104(8): 3507-3515 DOI:10.1007/s00253-020-10461-x. [99] Di MEO F, MARGARUCCI S, GALDERISI U, CRISPI S, PELUSO G. Curcumin, gut microbiota, and neuroprotection[J]. Nutrients, 2019, 11(10): 2426 DOI:10.3390/nu11102426. [100] EDWARDS RL, LUIS PB, VARUZZA PV, JOSEPH AI, PRESLEY SH, CHATURVEDI R, SCHNEIDER C. The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites[J]. The Journal of Biological Chemistry, 2017, 292(52): 21243-21252 DOI:10.1074/jbc.RA117.000123. [101] ARTACHO A, ISAAC S, NAYAK R, FLOR-DURO A, ALEXANDER M, KOO I, MANASSON J, SMITH PB, ROSENTHAL P, HOMSI Y, GULKO P, PONS J, PUCHADES-CARRASCO L, IZMIRLY P, PATTERSON A, ABRAMSON SB, PINEDA-LUCENA A, TURNBAUGH PJ, UBEDA C, SCHER JU. The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis[J]. Arthritis & Rheumatology, 2021, 73(6): 931-942. [102] SHANG JM, MA SR, ZANG CX, BAO XQ, WANG Y, ZHANG D. Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment[J]. Acta Pharmaceutica Sinica B, 2021, 11(5): 1213-1226 DOI:10.1016/j.apsb.2021.01.009. [103] REKDAL VM, BESS EN, BISANZ JE, TURNBAUGH PJ, BALSKUS EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism[J]. Science, 2019, 364(6445): eaau6323 DOI:10.1126/science.aau6323. [104] van KESSEL SP, FRYE AK, EL-GENDY AO, CASTEJON M, KESHAVARZIAN A, van DIJK G, EL AIDY S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease[J]. Nature Communications, 2019, 10: 310 DOI:10.1038/s41467-019-08294-y. [105] MEHTA RS, MAYERS JR, ZHANG YC, BHOSLE A, GLASSER NR, NGUYEN LH, MA WJ, BAE SN, BRANCK T, SONG K, SEBASTIAN L, PACHECO JA, SEO HS, CLISH C, DHE-PAGANON S, ANANTHAKRISHNAN AN, FRANZOSA EA, BALSKUS EP, CHAN AT, HUTTENHOWER C. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease[J]. Nature Medicine, 2023, 29(3): 700-709 DOI:10.1038/s41591-023-02217-7. [106] van KESSEL SP, de JONG HR, WINKEL SL, van LEEUWEN SS, NELEMANS SA, PERMENTIER H, KESHAVARZIAN A, EL AIDY S. Gut bacterial deamination of residual levodopa medication for Parkinson's disease[J]. BMC Biology, 2020, 18(1): 137 DOI:10.1186/s12915-020-00876-3. [107] TIAN JZ, LI C, DONG ZX, YANG YP, XING J, YU PJ, XIN Y, XU FM, WANG LW, MU YH, GUO XY, SUN Q, ZHAO GP, GU Y, QIN GJ, JIANG WH. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation[J]. Nature Metabolism, 2023, 5(5): 896-909 DOI:10.1038/s42255-023-00796-w. [108] ZAHRAN SA, ALI-TAMMAM M, HASHEM AM, AZIZ RK, ALI AE. Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota[J]. Scientific Reports, 2019, 9: 5508 DOI:10.1038/s41598-019-41894-8. [109] WILSON ID, NICHOLSON JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity[J]. Translational Research, 2017, 179: 204-222 DOI:10.1016/j.trsl.2016.08.002. [110] CREEKMORE BC, GRAY JH, WALTON WG, BIERNAT KA, LITTLE MS, XU YM, LIU J, GHARAIBEH RZ, REDINBO MR. Mouse gut microbiome-encoded β-glucuronidases identified using metagenome analysis guided by protein structure[J]. mSystems, 2019, 4(4): e00452-e00419. [111] MENG JJ, ABU YF, ZHANG Y, ZHOU YY, XIE Y, YAN Y, TAO JY, RAMAKRISHNAN S, CHEN C, ROY S. Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model[J]. British Journal of Pharmacology, 2023, 180(10): 1362-1378 DOI:10.1111/bph.16020. [112] BJÖRKHOLM B, BOK CM, LUNDIN A, RAFTER J, HIBBERD ML, PETTERSSON S. Intestinal microbiota regulate xenobiotic metabolism in the liver[J]. PLoS One, 2009, 4(9): e6958 DOI:10.1371/journal.pone.0006958. [113] ZEMANOVÁ N, ANZENBACHER P, ZAPLETALOVÁ I, JOUROVÁ L, HERMANOVÁ P, HUDCOVIC T, KOZÁKOVÁ H, VODIČKA M, PÁCHA J, ANZENBACHEROVÁ E. The role of the microbiome and psychosocial stress in the expression and activity of drug metabolizing enzymes in mice[J]. Scientific Reports, 2020, 10: 8529 DOI:10.1038/s41598-020-65595-9. [114] KUNO T, HIRAYAMA-KUROGI M, ITO S, OHTSUKI S. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels[J]. Scientific Reports, 2018, 8: 1253 DOI:10.1038/s41598-018-19545-1. [115] JARMUSCH AK, VRBANAC A, MOMPER JD, MA JD, ALHAJA M, LIYANAGE M, KNIGHT R, DORRESTEIN PC, TSUNODA SM. Enhanced characterization of drug metabolism and the influence of the intestinal microbiome: a pharmacokinetic, microbiome, and untargeted metabolomics study[J]. Clinical and Translational Science, 2020, 13(5): 972-984 DOI:10.1111/cts.12785. [116] SELWYN FP, CHENG SL, KLAASSEN CD, CUI JY. Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics[J]. Drug Metabolism and Disposition, 2016, 44(2): 262-274 DOI:10.1124/dmd.115.067504. [117] HU N, LIU X, MU QF, YU MM, WANG H, JIANG Y, CHEN R, WANG LY. The gut microbiota contributes to the modulation of intestinal CYP3A1 and P-gp in streptozotocin-induced type 1 diabetic rats[J]. European Journal of Pharmaceutical Sciences, 2021, 162: 105833 DOI:10.1016/j.ejps.2021.105833. [118] KLÜNEMANN M, ANDREJEV S, BLASCHE S, MATEUS A, PHAPALE P, DEVENDRAN S, VAPPIANI J, SIMON B, SCOTT TA, KAFKIA E, KONSTANTINIDIS D, ZIRNGIBL K, MASTRORILLI E, BANZHAF M, MACKMULL MT, HÖVELMANN F, NESME L, BROCHADO AR, MAIER LS, BOCK T, et al. Bioaccumulation of therapeutic drugs by human gut bacteria[J]. Nature, 2021, 597(7877): 533-538 DOI:10.1038/s41586-021-03891-8. [119] COHEN Z, KELLY L. Bioaccumulation as a mechanism of microbiome/drug interactions[J]. Trends in Microbiology, 2022, 30(2): 99-101 DOI:10.1016/j.tim.2021.12.003. [120] JAVDAN B, LOPEZ JG, CHANKHAMJON P, LEE YC J, HULL R, WU QH, WANG XJ, CHATTERJEE S, DONIA MS. Personalized mapping of drug metabolism by the human gut microbiome[J]. Cell, 2020, 181(7): 1661-1679.e22 DOI:10.1016/j.cell.2020.05.001. [121] GONG G, ZHOU SS, LUO RB, GESANG ZM, SUOLANG SZ. Metagenomic insights into the diversity of carbohydrate-degrading enzymes in the yak fecal microbial community[J]. BMC Microbiology, 2020, 20(1): 302 DOI:10.1186/s12866-020-01993-3. [122] TASSE L, BERCOVICI J, PIZZUT-SERIN S, ROBE P, TAP J, KLOPP C, CANTAREL BL, COUTINHO PM, HENRISSAT B, LECLERC M, DORÉ J, MONSAN P, REMAUD-SIMEON M, POTOCKI-VERONESE G. Functional metagenomics to mine the human gut microbiome for dietary fiber catabolic enzymes[J]. Genome Research, 2010, 20(11): 1605-1612 DOI:10.1101/gr.108332.110. [123] WESTERMANN AJ, VOGEL J. Cross-species RNA-seq for deciphering host-microbe interactions[J]. Nature Reviews Genetics, 2021, 22(6): 361-378 DOI:10.1038/s41576-021-00326-y. [124] ZHOU ZC, TRAN PQ, BREISTER AM, LIU Y, KIEFT K, COWLEY ES, KARAOZ U, ANANTHARAMAN K. METABOLIC: high-throughput profiling of microbial genomes for functional traits, metabolism, biogeochemistry, and community-scale functional networks[J]. Microbiome, 2022, 10(1): 33 DOI:10.1186/s40168-021-01213-8. [125] BILEN M, DUFOUR JC, LAGIER JC, CADORET F, DAOUD Z, DUBOURG G, RAOULT D. The contribution of culturomics to the repertoire of isolated human bacterial and archaeal species[J]. Microbiome, 2018, 6(1): 94 DOI:10.1186/s40168-018-0485-5. [126] DUBOURG G, BARON S, CADORET F, COUDERC C, FOURNIER PE, LAGIER JC, RAOULT D. From culturomics to clinical microbiology and forward[J]. Emerging Infectious Diseases, 2018, 24(9): 1683-1690 DOI:10.3201/eid2409.170995. [127] WANG XF, HOWE S, WEI XY, DENG FL, TSAI T, CHAI JM, XIAO YP, YANG H, MAXWELL CV, LI Y, ZHAO JC. Comprehensive cultivation of the swine gut microbiome reveals high bacterial diversity and guides bacterial isolation in pigs[J]. mSystems, 2021, 6(4): e0047721 DOI:10.1128/mSystems.00477-21.